Advertisement

Systemic inflammatory response in predicting outcomes of patients undergoing curative resection for oral squamous cell carcinoma

Published:November 10, 2021DOI:https://doi.org/10.1016/j.bjoms.2021.10.017

      Abstract

      This study aimed to evaluate the prognostic significance of the modified Glasgow prognostic score (mGPS), neutrophil:lymphocyte ratio (NLR), and platelet:lymphocyte ratio (PLR) in patients undergoing resection of oral squamous cell carcinoma (OSCC) with curative intent. We also aimed to explore the relation between activated systemic inflammation and adverse tumour characteristics. Between February 2006 and December 2019, data on 825 patients undergoing curative resection of OSCC were retrospectively gathered. Preoperative C-reactive protein and serum albumin levels were obtained to calculate a mGPS. Full blood count parameters were collected to calculate NLR and PLR values. Categorical factors were analysed using the chi squared test. Multivariate regression was performed to identify independent prognostic variables and the predictive value of each model generated. For disease-specific survival (DSS) and overall survival (OS), mGPS (DSS and OS both p<0.001), NLR (DSS and OS both p<0.001) and PLR (DSS and OS both p<0.001) were significant on univariate analysis. Independent predictive variables for DSS included mGPS, clinical node stage, categorised depth of tumour invasion, non-cohesive invasive front, and lymphovascular invasion. The concordance index was acceptable (0.756) for this model. Replacing mGPS with NLR or PLR as a marker of systemic inflammation demonstrated the same preoperative variables as independently predictive for DSS. The concordance index for these models were acceptable (NLR 0.76 and PLR 0.756). The systemic inflammatory response is prognostically significant in patients undergoing curative resection of OSCC. The potential link between an inflammatory tumour microenvironment and activated systemic inflammation merits further investigation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Liu S.A.
        • Wang C.C.
        • Jiang R.S.
        • et al.
        Pathological features and their prognostic impacts on oral cavity cancer patients among different subsites – a single institute’s experience in Taiwan.
        Sci Rep. 2017; 7: 7451
        • Valero C.
        • Zanoni D.K.
        • Pillai A.
        • et al.
        Host factors independently associated with prognosis in patients with oral cavity cancer.
        JAMA Otolaryngol Head Neck Surg. 2020; 146: 699-707
        • Roxburgh C.S.
        • McMillan D.C.
        Cancer and systemic inflammation: treat the tumour and treat the host.
        Br J Cancer. 2014; 110: 1409-1412
        • Proctor M.J.
        • Talwar D.
        • Balmar S.M.
        • et al.
        The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.
        Br J Cancer. 2010; 103: 870-876
        • Roxburgh C.S.
        • McMillan D.C.
        Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.
        Future Oncol. 2010; 6: 149-163
        • Proctor M.J.
        • Morrison D.S.
        • Talwar D.
        • et al.
        A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
        Eur J Cancer. 2011; 47: 2633-2641
        • Dolan R.D.
        • Lim J.
        • McSorley S.T.
        • et al.
        The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systemic review and meta-analysis.
        Sci Rep. 2017; 7: 16717
      1. Brierley J.D. Gospodarowicz M.K. Wittekind C. TNM classification of malignant tumours. 8th ed. Wiley Blackwell, 2017
        • Farhan-Alanie O.M.
        • McMahon J.
        • McMillan D.C.
        Systemic inflammatory response and survival in patients undergoing curative resection of oral squamous cell carcinoma.
        Br J Oral Maxillofac Surg. 2015; 53: 126-131
        • Nakayama M.
        • Tabuchi K.
        • Hara A.
        Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer.
        Head Neck. 2015; 37: 1745-1749
        • Hanai N.
        • Sawabe M.
        • Kimura T.
        • et al.
        The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
        Oncotarget. 2018; 9: 37008-37016
        • Chen H.H.
        • Chen I.H.
        • Liao C.T.
        • et al.
        Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study.
        Clin Otolaryngol. 2011; 36: 147-153
        • Marnell L.
        • Mold C.
        • Du Clos T.W.
        C-reactive protein: ligands, receptors and role in inflammation.
        Clin Immunol. 2005; 117: 104-111
        • Mantovani A.
        • Ponzetta A.
        • Inforzato A.
        • et al.
        Innate immunity, inflammation and tumour progression: double-edged swords.
        J Intern Med. 2019; 285: 524-532
        • Greten F.R.
        • Grivennikov S.I.
        Inflammation and cancer: triggers, mechanisms, and consequences.
        Immunity. 2019; 51: 27-41
        • Hiam-Galvez K.J.
        • Allen B.M.
        • Spitzer M.H.
        Systemic immunity in cancer.
        Nat Rev Cancer. 2021; 21: 345-359
        • Müller S.
        Oral lichenoid lesions: distinguishing the benign from the deadly.
        Modern Pathol. 2017; 30: S54-S67